cyrilzakka/clinical-trials huggingface dataset:
Screening Programme for Abdominal Aortic Aneurysm by Hand-Held-Ultrasonography in Primary Health Care

To determine the prevalence of Abdominal Aortic Aneurysm (AAA) in the Spanish men over 60 years through a screening program in Primary Health Care using a hand-held ultrasound and to analyze the relationship between cardiovascular risk factors and cardiovascular disease in patients with AAA.

Study includes a cohort of men over 60 years attented in primary health care centers of Consorci d'Atenció Primària de Salut d'Eixample (CAPSE).General practitioners complete an ultrasonography training in an ultrasound unit under supervision of experienced radiologists using a standard ultrasound equipment and hand-held ultrasound (Trademark: VScan, Manufacturer: General Electric, USA). All images and video are blindly evaluated by a radiologist in order to establish the concordance in the interpretation of images between general practitioners and radiologist. Kappa index will be used to study the agreement on the presence or absence of AAA. Multivariate logistic regression analysis will be used to determine the factors that influence the presence of AAA.

Eligibility Criteria:
Inclusion Criteria:

* Men 60 years or more
* Attending at primary health care center for any complaint

Exclusion Criteria:

* Subjects being hemodynamically unstable at presentation
* Subjects with previous AAA confirmed by abdominal ultrasound scan or another image diagnosis technique
* Subjects deemed to require emergent treatment at presentation or after initial history and physical examination.
Frequency of Orthostatic Hypotension in Patients Who Underwent Colonoscopy

Patients who will undergo colonoscopy accompanied by sedoanalgesia will be admitted at Aksaray Training and Research Hospital Gastroenterology Clinic between May and July 2024. Orthostatic hypotension will be evaluated after patients meet the discharge criteria in the postoperative recovery unit.

Patients over the age of 18 who apply to the endoscopy unit for colonoscopy will be included. Patients who will be excluded from the study; Patients with cognitive dysfunction for whom consent could not be obtained Patients who cannot walk

Routine ASA (American Society of Anesthesiologist) monitoring will be applied when patients are taken to the procedure room. Patients will be monitored for oxygen saturation with an oxygen saturation probe, non-invasive blood pressure monitoring, and heart rate and rhythm monitoring with an electrocardiogram. Patients will be given oxygen support via nasal cannula or mask. Patients will be given maintenance intravenous fluids. Patients will receive moderate to deep sedation/analgesia. At the end of the procedure, patients will be taken to the postoperative recovery unit and monitored. Patients will be evaluated according to the Aldrete score and a discharge decision will be made. When the decision to discharge the patients is made, they will first be seated and vital signs will be monitored when they are first placed in a sitting position and at the 3rd minute in the sitting position. Then, the patients will be stood up and vital signs will be monitored when they first stand up and at the 3rd minute. It will be noted whether patients develop additional symptoms. Patients who do not have symptoms and are decided to be discharged will be taken to a second waiting room and will be monitored under observation for a while.

Eligibility Criteria:
Inclusion Criteria:

* Patients over the age of 18 who apply to the endoscopy unit for colonoscopy will be included.

Exclusion Criteria:

* Patients with cognitive dysfunction for whom consent could not be obtained Patients who cannot walk
Prenatal Listening to Songs Composed for Pregnancy and Symptoms of Anxiety and Depression: a Pilot Study

Prenatal anxiety and depression are distressing for the expectant mother and can have adverse effects on her fetus and child. This study aimed to determine whether listening to specially composed songs would be an effective intervention for reducing symptoms of prenatal anxiety and depression over a period of 12 weeks.

Prenatal anxiety and depression has negative implications for both the mother and the developing child, including developmental disorders, low birth weight, and altered immune function. It is therefore very important both to detect and to help ameliorate symptoms of anxiety and depression in pregnant women. Many women do not want pharmacological interventions at this time, and with less severe symptoms it may not be appropriate. Thus there is a need to find non-pharmacological methods of intervention. Psychological therapies such as cognitive behavioural therapy or interpersonal therapy can be effective. But these are often not available for the large numbers of women who could benefit. Though there has been evidence that music has the ability reduce anxiety, no study has quantitatively measured prenatal anxiety and depression over a long period of time. Proof of efficacy could justify investment into music as an inexpensive, and non-stigmatizing method to reduce prenatal anxiety and depression and therefore benefit both the mother and child.

Eligibility Criteria:
Inclusion Criteria:

* English speaking women
* At least 18 years of age.
A Study to Determine Pharmacokinetics of Children Receiving Modigraf (Tacrolimus Granules) Following Solid Organ Transplantation

The purpose of this study is to find out how much of Modigraf is absorbed and used in the body and how fast it leaves the body (Pharmacokinetics). The results will then help to decide how much Modigraf in future can be given safely to children and young people following transplantation.

The primary objective of this study is to determine the pharmacokinetics (PK) of tacrolimus following oral administration of Modigraf, after the first oral dose and at steady state in paediatric subjects undergoing de novo allograft transplantation.

Eligibility Criteria:
Inclusion Criteria:

* The subject is the recipient of a solid organ (liver, kidney or heart) transplant. Multiorgan transplants are acceptable as long as one of the organs transplanted is liver, kidney or heart

Exclusion Criteria:

* The subject has previously received another organ transplant (including liver, kidney or heart re-transplantation)
* Subject has a high immunological risk, defined as a Panel Reactive Antibody (PRA) score \>50% in the previous 6 months (only applicable for renal transplant recipients)
* Cold ischemia time of the donor kidney greater than 30 hours (only applicable for renal transplant recipients)
* Subject receives an AB0 incompatible donor organ
* Subject has significant renal impairment, defined as having serum creatinine ≥230 μmol/l (≥2.6 mg/dl) pre-transplantation (not applicable for renal transplant recipients)
* Subject has significant liver disease, defined as having elevated Alanine Aminotransferase (ALT) and/or Asparate Aminotransferase (AST) and/or Total Bilirubin levels 3 times the upper value of the normal range during the 28 days prior to transplantation (not applicable for liver transplant recipients)
* Subject with pulmonary vascular resistance greater than 4 Wood units which is unresponsive to treatment
* Subjects with malignancies or a history of malignancy within the last 5 years
* Subject has a significant, uncontrolled systemic infection and/or severe diarrhea, vomiting, active upper gastrointestinal disorder that may affect the absorption of tacrolimus or has an active peptic ulcer
* Subject requires systemic immunosuppressive medication for any indication other than transplantation
* Recipient or donor known to be HIV, HCV or HBV positive
* Known allergy or intolerance to steroids, macrolide antibiotics, basiliximab or tacrolimus
* Subject is currently participating in another clinical trial and/or has been taking an investigational drug in the 3 months prior to transplantation
* Subject is unlikely to comply with the visits scheduled in the protocol
* Subjects taking or requiring to be treated with medication or substances prohibited by this protocol
Effect of an Interdisciplinary Spine Rehabilitation Program

The goal of this research project is to evaluate the effectiveness of the current interdisciplinary rehabilitation program (Revita) and follow-up trajectory for chronic lumbar spine disorders in the University Hospitals Leuven.


Eligibility Criteria:
Inclusion criteria

* Adults, age \> 18 years
* Spine problem for \> 6 weeks, needing interdisciplinary care (risk factors, failure of first line treatment, etc)
* Inclusion in Revita program
* Informed consent to participate

Exclusion criteria

* Patients without sufficient understanding of the Dutch language
* Unable to participate in 2h rehabilitation sessions with exercises
The Impact of Web 2.0 Tools on Nursing Education

This research was planned experimentally to investigate the effect of teaching supported by WEB 2.0 tools on the development of WEB pedagogical content knowledge of nursing students. Innovative learning technologies provide easy and fast access to information. One of the important opportunities provided by the Internet is that it facilitates the transfer of information in education and enables active learning thanks to WEB 2.0 applications.

The use of WEB 2.0 tools in nursing education provides significant benefits to the cognitive, affective and behavioral fields. Considering their important role in education, academic nurses' technological applications are critical to achieve good results in this context. For this reason, it is very important to shed light on the use of Web 2.0 tools for nursing education, to enlighten nurse candidates about the general use of Web 2.0 tools, and at the same time to discover the best technological practices they use.

In this study, a priori power analysis was performed before starting the study to determine the sample size. In the power analysis, it was determined that the number of samples should be 80, 40 interventional and 40 control, with a 0.05 significance level, 95% confidence interval, 95% power and a 5% margin of error.

SPSS 23.0 (Statistical Program for Social Sciences) package program will be used to evaluate the data obtained from the research. The suitability of variables to normal distribution will be examined visually (histograms, probability plots) and analytical methods (Kolmogorov-Smirnov test). When comparing control and intervention groups, independent groups t-test will be used for comparisons between normally distributed continuous variables, and chi-square test will be used for categorical variables. Comparing the scale scores before and after the application in the intervention group, if the data shows a normal distribution, paired t test will be applied, if it does not show a normal distribution, the Wilcoxon test will be applied. The relationships between variables will be evaluated using Pearson correlation analysis for normally distributed values, and Spearman correlation analysis for non-normally distributed values. Statistical significance level will be accepted as p\<0.05

Eligibility Criteria:
Inclusion Criteria:

Being a second year student in the nursing department Not having received training on WEB tools Taking the basic principles and practices course in nursing

Exclusion Criteria:

* Not being a second-year student in the nursing department Having training on WEB tools Not taking the basic principles and practices course in nursing
Nordic Cystectomy Study III - Transfusion

Around 7200 cases of Muscle Invasive Bladder Cancer are diagnosed annually in the Nordic countries combined. Muscle Invasive Bladder Cancer is an aggressive disease and it is linked with high mortality rates. The golden standard of treatment is radical cystectomy (RC) (the surgical removal of the bladder) and radical removal of lymph nodes in the pelvis. In addition to surgical treatment, and especially in cases where the tumour invades tissues surrounding the bladder or lymph nodes, chemotherapy is recommended. Chemotherapy can be administered before or after surgery, in a neoadjuvant (NAC) or adjuvant setting (AC). Although most patients recover well from surgery, there are significant risks regarding radical cystectomy. The greatest challenges in planning the treatment are making individual risk assessments and prognosis for the treated patients. Neoadjuvant chemotherapy is also insufficiently used and it is hard to predict how the tumour responds to chemotherapy.

The purpose of this study is to collect prospective clinical data on radical cystectomy -patients in co-operation with other Nordic countries: Sweden, Denmark, Iceland and Norway. The collected data is used to validate existing prediction tools and discover novel tools for prediction of morbidity related to RC and prediction of oncological outcome after RC. The study is divided into three sub-studies. Transfusions during RC and the time of hospitalization after the surgery are associated poorer oncological outcome when compared to those patients who do not need transfusions. The third study focuses on the oncological outcomes in patients receiving blood transfusions. As there are some conflicting reports and the finding is not properly validated, we aim to validate the effect of transfusions on survival after RC.

The number of transfusions during RC and the time between surgery and discharge from hospital will be recorded. Patient cohort will be divided into patients receiving transfusions and not receiving transfusion. The primary end point is patients receiving transfusion and its effect on cancer specific mortality at 24 months. For patients receiving NAC, additional secondary end-point is complete response (pT0N0) rate at RC.


Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed urinary BC planned to be treated with RC with or without neoadjuvant chemotherapy.
* Histologically confirmed urinary BC planned to be treated with palliative cystectomy
* Signed informed consent
* Patient age \>18 years

Exclusion Criteria:

* RC for other reasons than BC
* Other forms of surgical treatment of BC than RC (e.g. bladder resection).
* Patient unwillingness to participate in the study for any reason (i.e. lack of signed consent).
Diverse Training Programs and Sarcopenia in Postmenopausal Women

This study explored preventive measures for sarcopenia in apparently healthy postmenopausal women. The investigators implemented a short Nordic walking intervention, Bungy Pumo exercises and strength training, and conducted a 3-month training program as an intervention method. The subjects divided into the NW (Nordic walking) test group, the ST (Strength Training) test group, BP (Bungy Pump exercises) test group and the control group, which engaged in regular daily activities without any additional physical exercise. The collected experimental data then processed and analyzed to objectively assess the benefits and limitations of different interventions.

The tests were conducted twice (before and after the training period). Each test lasted two days and will be preceded by a 7-day measurement of physical activity using sport testers. On the first day, blood tests, microbiota, body composition and a preliminary analysis of diet diaries were performed. On the second day, physical fitness tests were carried out in the Physical Exercise Laboratory of the AWFiS in Gdańsk. Biological material (blood serum and feces) was frozen for testing by the project contractors in the Laboratory of Genetics in Sports of the AWFiS. The subjects were required to keep a diet diary in which they recorded meals during the 3 days preceding the blood and intestinal microbiota test.

Eligibility Criteria:
Inclusion Criteria:

Postmenopausal women over 60 years old (i.e. more than 12 months since their last menstrual cycle).

There were no contraindications to exercise after case reports and initial diagnosis.

Informed consent must be signed, agreeing to participate in research and physical exercise programs.

Exclusion Criteria:

Uncontrolled high blood pressure. Coronary artery disease. Rheumatoid arthritis. Type 2 diabetes. Respiratory diseases and lung diseases. Are taking or have used antibiotics and/or antifungal therapy in the past 4 weeks.

Unwillingness to stick to a prescribed schedule.
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBL) (MK-2140-011/waveLINE-011)

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing.

The goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.


Eligibility Criteria:
Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Has histologically confirmed diagnosis of germinal center B-cell (GCB) subtype of diffuse large B-cell lymphoma (DLBCL), by prior biopsy, according to the World Health Organization (WHO) classification of neoplasms of the hematopoietic and lymphoid tissues.
* Has positron emission tomography (PET) positive disease at screening, defined as 4 to 5 on the Lugano 5-point scale.
* Has received no prior treatment for their DLBCL.
* Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART).
* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load prior to randomization.
* Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening.

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Has a history of transformation of indolent disease to DLBCL.
* Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL) or Grey zone lymphoma.
* Has Ann Arbor Stage I DLBCL.
* Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (\<6 months prior to enrollment), myocardial infarction (\<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication.
* Has clinically significant pericardial or pleural effusion.
* Has ongoing Grade \>1 peripheral neuropathy.
* Has a demyelinating form of Charcot-Marie-Tooth disease.
* HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
* Has ongoing corticosteroid therapy.
* Known additional malignancy that is progressing or has required active treatment within the past 2 years.
* Known active central nervous system (CNS) lymphoma.
* Has active autoimmune disease that has required systemic treatment in the past 2 years.
* Has active infection requiring systemic therapy.
* Has active HBV (defined as HBsAg positive and detectable HBV deoxyribonucleic acid (DNA)) and HCV (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid (RNA)) infection.
* Has history of stem cell/solid organ transplant.
Helping Parents to Decide Whether They Want to be With Their Child During Anesthesia Induction

Children are distressed at anesthesia induction and this distress can result in maladaptive recovery outcomes. Having parents be present at anesthesia induction (PPIA) has been suggested as a potential intervention to decrease children's distress, and this intervention is widely favored by parents. However, to date, PPIA has not been found to be effective in reducing children's anxiety. The lack of efficacy may be attributable to the fact that parents have generally not been prepared for PPIA. The one study that prepared parents (as part of a larger preoperative preparation program) found that PPIA with preparation was superior to PPIA as previously studied (without preparation). Unfortunately, this program is resource intensive and therefore is not clinically feasible. This study will compare PPIA with a clinically feasible preparation program to PPIA with standard care (minimal preparation). Should our intervention show evidence of efficacy, the investigators will have designed a program that is easily translatable to everyday clinical practice. This will, in turn, reduce children's anxiety, improve postoperative outcomes and increase parental satisfaction.


Eligibility Criteria:
Inclusion Criteria:

* Ages 2 to 10
* Scheduled for elective surgical procedure at IWK Health Centre
* Mask induction
* ASA classification I or II

Exclusion Criteria:

* Intravenous induction
* Diagnosed development delay
* ASA classification III or higher
* Pre-medication with benzodiazepine
Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders

The primary goal of this study is to investigate metabolic changes and maintaining efficacy in stabilized patients with bipolar disorders who have pharmacologically induced weight gain.

* reduced treatment adherence due to metabolic side effects
* suggested advantages of aripiprazole in metabolic profile over other antipsychotics or mood stabilizers
* randomized trial of switch from previous drugs to aripiprazole

Eligibility Criteria:
Inclusion Criteria:

* patients with bipolar disorders (I, II, NOS) diagnosed with DSM-IV criteria
* age between 18 and 65
* Decisional capacity is adequate to provide informed consent or has an authorized appropriate surrogate decision maker. in a syndromal remission state at least for 2 months : CGI - BP ≤ 3
* patients who have exhibited a clinically significant increase in body weight after starting the administration of their current antipsychotic (ie \>7% weight gain)

Exclusion Criteria:

* diagnosis of eating disorder, substance abuse, and psychotic disorder
* history of neurological and medical illness
* pregnant or breast feeding women